metformin has been researched along with Head and Neck Neoplasms in 38 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin intake was associated with a favorable outcome in HNM patients, providing possible therapeutic implications for future adjuvant treatment regimes." | 5.72 | Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. ( Ettl, T; Fischer, R; Gerken, M; Lindner, SR; Ludwig, N; Reichert, TE; Schimnitz, S; Spanier, G; Spoerl, S; Taxis, J, 2022) |
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 5.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| "Oral squamous cell carcinoma (OSCC) is one of the most common malignancies and has a high mortality, posing a great threat to both human physical and mental health." | 3.01 | Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma. ( Liu, J; Qiao, X; Zhao, J, 2023) |
| "Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design." | 2.94 | Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020) |
| "Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery." | 2.84 | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. ( Birbe, R; Cognetti, D; Cotzia, P; Curry, J; Duddy, E; Gill, K; Johnson, J; Leiby, B; Lin, Z; Luginbuhl, A; Martinez-Outschoorn, U; Menezes, DW; Mollaee, M; Reyzer, M; Sprandio, J; Tassone, P; Tuluc, M; Vidal, MD; Zhan, T, 2017) |
| "Metformin has been associated with improved survival outcomes in various malignancies." | 2.66 | The Association between Metformin and Survival of Head and Neck Cancer: A Systematic Review and Meta-Analysis of 7 Retrospective Cohort Studies. ( Fu, T; Liu, Y; Wang, Y; Yang, G; Yu, C; Zhang, ZJ, 2020) |
| " Qualitative synthesis also suggests an apparently dose-response relationship and increased benefit when administered alone." | 2.58 | Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review. ( Estrugo Devesa, A; Jané-Salas, E; López-López, J; Saka Herrán, C, 2018) |
| "Paired pre- and post-treatment primary HNSCC tumor samples were stained for CD8+ and FoxP3+." | 1.91 | CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition. ( Alnemri, A; Argiris, A; Curry, J; Fiorella, M; Harshyne, L; Johnson, J; Linnenbach, A; Luginbuhl, A; Martinez-Outschoorn, U; Philips, R; Solomides, C; South, A; Stapp, R; Sussman, S; Tuluc, M, 2023) |
| "Oral squamous cell carcinoma (OSCC) is considered as the sixth most common cancer worldwide characterized by high invasiveness, high metastasis rate and high mortality." | 1.91 | Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing. ( Chen, C; Ji, M; Li, X; Lv, Y; Ma, X; Qi, Y; Wang, Y; Xing, D; Xu, W; Zhang, J; Zhang, W; Zhao, J; Zhou, C, 2023) |
| "Head and neck cancers (HNC), the sixth most common malignancy worldwide, require a multimodal approach, especially in advanced stages and cancer specific treatment is often associated with therapeutic failure and severe toxicities even if it is delivered according to current standards." | 1.91 | Implications of diabetes in head and neck cancer - A single center real-world data. ( Badulescu, F; Mirestean, CC; Stan, MC, 2023) |
| "However, the role of IL-1RA in oral squamous cell carcinoma (OSCC), in particular the underlying mechanisms, remains to be elucidated." | 1.91 | IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway. ( Chan, LP; Chen, YK; Hu, SC; Hung, AC; Lo, S; Nguyen, HDH; Wang, YM; Wang, YY; Yuan, SF, 2023) |
| "Retrospective studies have shown that head and neck squamous cell carcinoma (HNSCC) patients taking metformin demonstrate superior survival compared to their counterparts." | 1.91 | Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. ( Chen, A; Chen, G; Florez, M; Hernandez, DJ; Hilsenbeck, SG; Jhaveri, P; Kemnade, JO; Miller-Chism, C; Sabichi, A; Sandulache, VC; Shaun, B; Skinner, HD; Zhang, J, 2023) |
| "Metformin increased HNSCC NK cell cytotoxicity and inhibited the CXCL1 pathway while stimulating the STAT1 pathway within HNSCC NK cells." | 1.72 | Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. ( Borchers, M; Crago, A; Crist, M; Curry, J; Fuhrman, B; Gulati, S; Karivedu, V; Lehn, MA; Martinez-Outschoorn, U; Medvedovic, M; Palackdharry, S; Stone, T; Takiar, V; Wise-Draper, TM; Yaniv, B, 2022) |
| "Metformin intake was associated with a favorable outcome in HNM patients, providing possible therapeutic implications for future adjuvant treatment regimes." | 1.72 | Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. ( Ettl, T; Fischer, R; Gerken, M; Lindner, SR; Ludwig, N; Reichert, TE; Schimnitz, S; Spanier, G; Spoerl, S; Taxis, J, 2022) |
| "Chemotherapy in head and neck squamous cell carcinoma (HNSCC) has many systemic side effects, as well as hypoxia-induced chemoresistance." | 1.56 | Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma. ( Cai, Y; Cheng, W; Han, W; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Zou, H, 2020) |
| "Metformin may reduce the progression of head and neck squamous cell carcinoma (HNSCC); however, whether metformin acts by altering the host metabolism or targets cancer-initiating cells remains poorly understood." | 1.51 | Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells. ( Amornphimoltham, P; Ando, T; Chen, Q; Goto, Y; Gutkind, JS; Lippman, SM; Murphy, AN; Tamayo, P; Wang, Z; Wu, VH; Wu, X; Yeerna, H; Zhang, X, 2019) |
| "Metformin was protective among patients ≤60 years of age (HR for the period of 0-2 years post-diagnosis: 0." | 1.51 | Metformin exposure and survival in head and neck cancer: A large population-based cohort study. ( Alcusky, M; Karagiannis, T; Keith, SW; Louis, DZ; Maio, V; Rabinowitz, C, 2019) |
| "Patients with head and neck cancer undergoing concurrent CRT along with metformin treatment require more careful multidisciplinary assessment and supportive care to ensure successful completion of treatment and avoid treatment-related toxicities." | 1.46 | Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. ( Chang, PH; Chen, EY; Chou, WC; Hsieh, JC; Wang, CH; Yang, SW; Yeh, KY, 2017) |
| "Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM)." | 1.46 | Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. ( Blitzer, A; Lerner, MZ; Mor, N; Paek, H; Strome, M, 2017) |
| "The risk of head and neck cancer at the end of 2011 was determined." | 1.42 | Effect of metformin on the incidence of head and neck cancer in diabetics. ( Lin, C; Lin, SW; Lin, YS; Weng, SF; Yen, YC, 2015) |
| "Most squamous cell carcinomas of the head and neck (HNSCC) exhibit a persistent activation of the PI3K-mTOR signaling pathway." | 1.42 | Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. ( Carey, TE; Ferris, RL; Gangane, N; Gutkind, JS; Komarck, CM; Madera, D; Martin, D; McHugh, JB; Molinolo, AA; Schneider, A; Seethala, RR; Vitale-Cross, L; Walline, HM; William, WN, 2015) |
| "Dasatinib is a Bcr-bl and Src kinase inhibitor that has potential against HNSCC." | 1.40 | Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. ( Chen, CC; Huang, LY; Huang, WC; Lin, YC; Lin, YT; Wei, TT; Wu, MH, 2014) |
| "Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients." | 1.40 | Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival. ( Sandulache, VC; Skinner, HD; Woo, SH; Yang, L, 2014) |
| "Metformin use has been associated with a decreased risk of some cancers, although data on head and neck cancer (HNC) are scarce." | 1.40 | Metformin and the risk of head and neck cancer: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, CR, 2014) |
| "Curcumin has been found to possess anti-cancer activities via its effect on a variety of biological pathways." | 1.39 | Targeting EP4 by curcumin through cross talks of AMP-dependent kinase alpha and p38 mitogen-activated protein kinase signaling: the role of PGC-1α and Sp1. ( Chen, J; Hann, SS; Wang, Z; Wu, J; Zhao, S; Zheng, F, 2013) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer in the world; the main risk factors are alcohol and tobacco use." | 1.38 | Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. ( Agarwal, C; Agarwal, R; Deep, G; Kaur, M; Sikka, A, 2012) |
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 1.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (60.53) | 24.3611 |
| 2020's | 15 (39.47) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, MT | 1 |
| Choe, HC | 1 |
| Kim, BH | 1 |
| Ahn, SG | 1 |
| Curry, J | 3 |
| Alnemri, A | 1 |
| Philips, R | 1 |
| Fiorella, M | 1 |
| Sussman, S | 1 |
| Stapp, R | 1 |
| Solomides, C | 1 |
| Harshyne, L | 1 |
| South, A | 1 |
| Luginbuhl, A | 2 |
| Tuluc, M | 2 |
| Martinez-Outschoorn, U | 3 |
| Argiris, A | 1 |
| Linnenbach, A | 1 |
| Johnson, J | 2 |
| Lin, YC | 3 |
| Chen, BS | 1 |
| Crist, M | 1 |
| Yaniv, B | 1 |
| Palackdharry, S | 1 |
| Lehn, MA | 1 |
| Medvedovic, M | 1 |
| Stone, T | 1 |
| Gulati, S | 2 |
| Karivedu, V | 1 |
| Borchers, M | 1 |
| Fuhrman, B | 1 |
| Crago, A | 1 |
| Takiar, V | 2 |
| Wise-Draper, TM | 2 |
| Ji, M | 2 |
| Lv, Y | 2 |
| Chen, C | 2 |
| Xing, D | 2 |
| Zhou, C | 2 |
| Zhao, J | 3 |
| Qi, Y | 2 |
| Zhang, J | 3 |
| Wang, Y | 5 |
| Ma, X | 2 |
| Xu, W | 4 |
| Zhang, W | 2 |
| Li, X | 3 |
| Spoerl, S | 2 |
| Gerken, M | 1 |
| Schimnitz, S | 1 |
| Taxis, J | 1 |
| Fischer, R | 1 |
| Lindner, SR | 1 |
| Ettl, T | 1 |
| Ludwig, N | 1 |
| Reichert, TE | 1 |
| Spanier, G | 1 |
| Shanchun, H | 1 |
| You, P | 1 |
| Sujuan, N | 1 |
| Xuebing, Z | 1 |
| Yijie, B | 1 |
| Xiaohui, X | 1 |
| Jianming, H | 1 |
| La, N | 1 |
| Zhehui, B | 1 |
| Qi, L | 1 |
| Wulong, J | 1 |
| Mirestean, CC | 1 |
| Stan, MC | 1 |
| Badulescu, F | 1 |
| Yuan, SF | 1 |
| Wang, YM | 1 |
| Chan, LP | 1 |
| Hung, AC | 1 |
| Nguyen, HDH | 1 |
| Chen, YK | 1 |
| Hu, SC | 1 |
| Lo, S | 1 |
| Wang, YY | 1 |
| Kemnade, JO | 1 |
| Florez, M | 1 |
| Sabichi, A | 1 |
| Jhaveri, P | 1 |
| Chen, G | 1 |
| Chen, A | 1 |
| Miller-Chism, C | 1 |
| Shaun, B | 1 |
| Hilsenbeck, SG | 1 |
| Hernandez, DJ | 1 |
| Skinner, HD | 3 |
| Sandulache, VC | 3 |
| Liu, J | 1 |
| Qiao, X | 1 |
| Desai, J | 1 |
| Palackdharry, SM | 1 |
| Morris, JC | 1 |
| Zhu, Z | 1 |
| Jandarov, R | 1 |
| Riaz, MK | 1 |
| Mierzwa, M | 1 |
| Gutkind, JS | 3 |
| Molinolo, A | 1 |
| Desai, PB | 1 |
| Sadraei, NH | 1 |
| Veitz-Keenan, A | 1 |
| Silvestre Calle, TD | 1 |
| Bergamini, M | 1 |
| Song, C | 1 |
| Tang, C | 1 |
| Ran, J | 1 |
| Wei, Z | 1 |
| Zou, H | 1 |
| Cheng, W | 1 |
| Cai, Y | 1 |
| Han, W | 1 |
| Fu, T | 1 |
| Liu, Y | 1 |
| Yang, G | 1 |
| Yu, C | 1 |
| Zhang, ZJ | 1 |
| Wei, J | 1 |
| Huang, J | 1 |
| Kuang, Y | 1 |
| Li, Y | 1 |
| Zhong, D | 1 |
| Song, J | 2 |
| Chang, PH | 1 |
| Yeh, KY | 1 |
| Wang, CH | 1 |
| Chen, EY | 1 |
| Yang, SW | 1 |
| Chou, WC | 1 |
| Hsieh, JC | 1 |
| Verma, A | 1 |
| Rich, LJ | 1 |
| Vincent-Chong, VK | 1 |
| Seshadri, M | 1 |
| Stokes, WA | 1 |
| Eguchi, M | 1 |
| Amini, A | 1 |
| Hararah, MK | 1 |
| Ding, D | 1 |
| McDermott, JD | 1 |
| Bradley, CJ | 1 |
| Karam, SD | 1 |
| Saka Herrán, C | 1 |
| Jané-Salas, E | 1 |
| Estrugo Devesa, A | 1 |
| López-López, J | 1 |
| Yang, J | 1 |
| Guo, Y | 1 |
| Seo, W | 1 |
| Zhang, R | 1 |
| Lu, C | 1 |
| Luo, L | 1 |
| Paul, B | 1 |
| Yan, W | 1 |
| Saxena, D | 1 |
| Wu, X | 1 |
| Yeerna, H | 1 |
| Goto, Y | 1 |
| Ando, T | 1 |
| Wu, VH | 1 |
| Zhang, X | 1 |
| Wang, Z | 2 |
| Amornphimoltham, P | 1 |
| Murphy, AN | 1 |
| Tamayo, P | 1 |
| Chen, Q | 1 |
| Lippman, SM | 1 |
| Alcusky, M | 1 |
| Keith, SW | 1 |
| Karagiannis, T | 1 |
| Rabinowitz, C | 1 |
| Louis, DZ | 1 |
| Maio, V | 1 |
| Lee, DJ | 1 |
| McMullen, CP | 1 |
| Foreman, A | 1 |
| Huang, SH | 1 |
| Lu, L | 1 |
| de Almeida, JR | 1 |
| Liu, G | 1 |
| Bratman, SV | 1 |
| Goldstein, DP | 1 |
| Hann, SS | 1 |
| Chen, J | 1 |
| Wu, J | 1 |
| Zheng, F | 1 |
| Zhao, S | 1 |
| Wu, MH | 1 |
| Wei, TT | 1 |
| Huang, WC | 1 |
| Huang, LY | 1 |
| Lin, YT | 1 |
| Chen, CC | 1 |
| Yen, YC | 1 |
| Lin, C | 1 |
| Lin, SW | 1 |
| Lin, YS | 1 |
| Weng, SF | 1 |
| Woo, SH | 2 |
| Yang, L | 1 |
| Becker, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Bodmer, M | 1 |
| Rêgo, DF | 1 |
| Pavan, LM | 1 |
| Elias, ST | 1 |
| De Luca Canto, G | 1 |
| Guerra, EN | 1 |
| Madera, D | 1 |
| Vitale-Cross, L | 1 |
| Martin, D | 1 |
| Schneider, A | 1 |
| Molinolo, AA | 1 |
| Gangane, N | 1 |
| Carey, TE | 1 |
| McHugh, JB | 1 |
| Komarck, CM | 1 |
| Walline, HM | 1 |
| William, WN | 1 |
| Seethala, RR | 1 |
| Ferris, RL | 1 |
| Kwon, M | 1 |
| Roh, JL | 1 |
| Lee, SW | 1 |
| Kim, SB | 1 |
| Choi, SH | 1 |
| Nam, SY | 1 |
| Yang, LP | 1 |
| Chuang, HC | 1 |
| Fitzgerald, A | 1 |
| Lee, HY | 1 |
| Pickering, C | 1 |
| Myers, JN | 2 |
| Figueiredo, RA | 1 |
| Weiderpass, E | 1 |
| Tajara, EH | 1 |
| Ström, P | 1 |
| Carvalho, AL | 1 |
| de Carvalho, MB | 1 |
| Kanda, JL | 1 |
| Moyses, RA | 1 |
| Wünsch-Filho, V | 1 |
| Lerner, MZ | 1 |
| Mor, N | 1 |
| Paek, H | 1 |
| Blitzer, A | 1 |
| Strome, M | 1 |
| Tassone, P | 1 |
| Vidal, MD | 1 |
| Menezes, DW | 1 |
| Sprandio, J | 1 |
| Mollaee, M | 1 |
| Cotzia, P | 1 |
| Birbe, R | 1 |
| Lin, Z | 1 |
| Gill, K | 1 |
| Duddy, E | 1 |
| Zhan, T | 1 |
| Leiby, B | 1 |
| Reyzer, M | 1 |
| Cognetti, D | 1 |
| Ow, TJ | 1 |
| Pickering, CR | 1 |
| Frederick, MJ | 1 |
| Zhou, G | 1 |
| Fokt, I | 1 |
| Davis-Malesevich, M | 1 |
| Priebe, W | 1 |
| Sikka, A | 1 |
| Kaur, M | 1 |
| Agarwal, C | 1 |
| Deep, G | 1 |
| Agarwal, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck[NCT03618654] | Phase 1 | 38 participants (Actual) | Interventional | 2018-11-01 | Active, not recruiting | ||
| Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.[NCT02083692] | Early Phase 1 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma[NCT02325401] | Phase 1 | 20 participants (Actual) | Interventional | 2015-05-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cohorts of patients received escalating doses of metformin (2000 mg, 2550 mg, or 3000 mg divided into daily doses) with a 7-day to 14-day lead-in prior to CRT based on the modified toxicity probability interval design to allow for possible re-escalation after previous de-escalation and to maximize the ability to identify the maximum tolerated dose (MTD). Patients continued to receive metformin for the duration of CRT as tolerated. (NCT02325401)
Timeframe: 24 months
| Intervention | mg (Number) |
|---|---|
| Metformin (2000mg) With Chemoradiation | NA |
| Metformin (2550mg) With Chemoradiation | NA |
| Metformin (3000mg) With Chemoradiation | NA |
Patients were evaulated at 36 months to determine if there was recurrence of disease. (NCT02325401)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.Any participants with any adverse event at any grade was included. Adverse events were collected during the on study period of 21 weeks up to three months after the study for a total of 34 weeks. (NCT02325401)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 7 |
| Metformin (3000mg) With Chemoradiation | 4 |
2 year overall survival (NCT02325401)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 5 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
2-year progression free survival (NCT02325401)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
5 reviews available for metformin and Head and Neck Neoplasms
| Article | Year |
|---|---|
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2023 |
Limited Evidence Suggests Metformin Might Be Beneficial to Reduce Head and Neck Cancer Risk and Increase Overall Survival, While Any Benefit With Antiinflammatory Drugs Is Inconsistent.
Topics: Head and Neck Neoplasms; Humans; Metformin | 2019 |
The Association between Metformin and Survival of Head and Neck Cancer: A Systematic Review and Meta-Analysis of 7 Retrospective Cohort Studies.
Topics: Head and Neck Neoplasms; Humans; Hypoglycemic Agents; Metformin; Prospective Studies; Retrospective | 2020 |
Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Case-Control Studies; Cohort Studi | 2018 |
Effects of metformin on head and neck cancer: a systematic review.
Topics: Head and Neck Neoplasms; Humans; Metformin | 2015 |
2 trials available for metformin and Head and Neck Neoplasms
| Article | Year |
|---|---|
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; M | 2017 |
31 other studies available for metformin and Head and Neck Neoplasms
| Article | Year |
|---|---|
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani | 2022 |
CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Topics: CD8-Positive T-Lymphocytes; Head and Neck Neoplasms; Humans; Lymphocytes, Tumor-Infiltrating; Metfor | 2023 |
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study.
Topics: Cohort Studies; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Humans; Melanoma; Metformin; Neo | 2022 |
Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Gene Expression Regulation, Neoplastic; Head and Nec | 2023 |
Implications of diabetes in head and neck cancer - A single center real-world data.
Topics: Diabetes Mellitus; Head and Neck Neoplasms; Humans; Metformin; Platinum; Prognosis | 2023 |
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D | 2023 |
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
Topics: Head and Neck Neoplasms; Humans; Metformin; Prospective Studies; Retrospective Studies; Squamous Cel | 2023 |
Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chlorophyllides; Cisplati | 2020 |
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2021 |
Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
Topics: Aged; Chemoradiotherapy; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Hypoglycemi | 2017 |
Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Hemoglobins; | 2018 |
Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Cohort Studies; Combined | 2018 |
Targeting cellular metabolism to reduce head and neck cancer growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Synergis | 2019 |
Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Elec | 2019 |
Metformin exposure and survival in head and neck cancer: A large population-based cohort study.
Topics: Aged; Female; Head and Neck Neoplasms; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle A | 2019 |
Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Head an | 2019 |
Targeting EP4 by curcumin through cross talks of AMP-dependent kinase alpha and p38 mitogen-activated protein kinase signaling: the role of PGC-1α and Sp1.
Topics: Adenylate Kinase; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Down-Regula | 2013 |
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C | 2014 |
Effect of metformin on the incidence of head and neck cancer in diabetics.
Topics: Adult; Age Distribution; Aged; Case-Control Studies; Comorbidity; Diabetes Mellitus; Disease-Free Su | 2015 |
Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cel | 2014 |
Metformin and the risk of head and neck cancer: a case-control analysis.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Diabetes Mellitus, Type 2; Fe | 2014 |
Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Case-Control Studies; Cell Cycle; C | 2015 |
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N | 2015 |
Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p | 2016 |
Diabetes mellitus, metformin and head and neck cancer.
Topics: Adult; Diabetes Mellitus; Female; Head and Neck Neoplasms; Humans; Hypoglycemic Agents; Male; Metfor | 2016 |
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human | 2017 |
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol | 2011 |
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
Topics: beta-Transducin Repeat-Containing Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife | 2012 |